Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iron replacement therapy for iron deficiency anemia in inflammatory bowel disease
2016-001772-30Phase 3Terminated
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ferric carboxymaltose, sodium ferric gluconate and Iron in iron deficiency anemia (IDA) and inflammatory bowel disease (IBD) (3 arms), sponsored by IRCCS San Matteo Foundation. Primary endpoint: Proportion of patients responsive to iron supplementation at week 8. Started Jun 2021; status: terminated.
02
Drugs
ferric carboxymaltosesodium ferric gluconateIron
03
Conditions
iron deficiency anemia (IDA)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2016-001772-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001772-30.